W. Kimryn Rathmell, MD, PhD, will share updates on her first months as director of the National Cancer Institute and continued progress on President Joe Biden’s Cancer Moonshot initiative during two different sessions at the Annual Meeting.

Annual Meeting Program Chairs Keith T. Flaherty, MD, FAACR, and Christina Curtis, PhD, MSc, preview notable items on Saturday’s schedule to help you plan your day.

A packed schedule of 41 educational sessions and 12 methods workshops are available Saturday for attendees who have added the Educational Program Pass to their Annual Meeting registrations.

Representatives from the U.S. Food and Drug Administration will join with leaders from academia, industry, and the patient advocacy community to discuss the impact of regulatory science on the evaluation of new cancer medicines.

A series of three sessions will provide an exciting, behind-the-scenes glimpse at the inventive and state-of-the-art strategies in drug design and development in oncology.

A track of sessions will allow Annual Meeting attendees to review recent progress in the understanding and treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma.